Enovis Co. (NYSE:ENOV - Get Free Report) was the recipient of a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 5,000,000 shares, a decrease of 5.1% from the January 15th total of 5,270,000 shares. Currently, 9.0% of the company's stock are short sold. Based on an average daily trading volume, of 810,800 shares, the days-to-cover ratio is currently 6.2 days.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Confluence Investment Management LLC acquired a new position in Enovis in the fourth quarter valued at approximately $3,494,000. Chartwell Investment Partners LLC boosted its holdings in shares of Enovis by 25.6% during the 3rd quarter. Chartwell Investment Partners LLC now owns 201,652 shares of the company's stock worth $8,681,000 after purchasing an additional 41,089 shares during the last quarter. Geode Capital Management LLC grew its holdings in Enovis by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 921,437 shares of the company's stock valued at $39,678,000 after buying an additional 80,165 shares in the last quarter. UMB Bank n.a. increased its stake in shares of Enovis by 128.2% in the 4th quarter. UMB Bank n.a. now owns 778 shares of the company's stock worth $34,000 after acquiring an additional 437 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Enovis during the third quarter worth about $1,050,000. Hedge funds and other institutional investors own 98.45% of the company's stock.
Shares of NYSE:ENOV opened at $43.89 on Tuesday. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The business has a 50 day simple moving average of $45.30 and a two-hundred day simple moving average of $44.33. Enovis has a 1 year low of $38.27 and a 1 year high of $65.03. The firm has a market capitalization of $2.50 billion, a PE ratio of -20.04 and a beta of 1.94.
Separately, Needham & Company LLC reiterated a "buy" rating and set a $65.00 price objective on shares of Enovis in a research report on Thursday, November 7th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $64.83.
Get Our Latest Analysis on ENOV
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Enovis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enovis wasn't on the list.
While Enovis currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.